A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

Novo Nordisk A/S

Summary

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

Eligibility

Age range: 18–64 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus greater than or equal to (\>=) 180 days before screening. * Glycated haemoglobin (HbA1c) 7.0-10.5 percent (%) (53-91 \[millimoles per mole\] mmol/mol) (both inclusive) as determined by the central laboratory at screening. * Stable daily dose \>= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator. * Body mass index (BMI) be…

Interventions

Drug
CagriSema
Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.
Drug
Placebo CagriSema
Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Locations (61)

Arkansas Clinical Research
Little Rock, Arkansas
Paradigm Clinical Research
San Diego, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Future Medical Research
Longwood, Florida
New Horizon Research Center
Miami, Florida